spray-dried-vaccine-formulation
The reliance on a continuous cold chain leads to significant vaccine waste and logistical hurdles. Spray drying technology presents a practical path to developing more robust, thermostable vaccine formulations. Discover how this innovative approach can solve your stability challenges.
Menu
Advancing Vaccine Stability: A Practical Look at Spray Drying
2. Typical Market Trends
FAQ
1. Current Situation
3. Current Challenges and How They Are Solved
4. How Leukocare Can Support These Challenges
5. Value Provided to Customers
Advancing Vaccine Stability: A Practical Look at Spray Drying
If you're a Director of CMC or Drug Product Development, your goal is a stable, effective, and manufacturable vaccine. Liquid formulations have long been the default, but relying on a continuous cold chain brings big logistical and financial hurdles. The World Health Organization estimates that up to 50% of vaccines are wasted globally each year, often due to cold chain failures [1, 7]. This is where drying technologies, particularly spray drying, come into play, offering a path to more robust, thermostable vaccines [2].
1. Current Situation
Most vaccines are biomolecules that are inherently unstable outside of a narrow temperature range, typically 2–8°C. This means you need a cold chain—a series of refrigerators and freezers stretching from the manufacturing plant to the patient [15, 3]. Keeping this chain going is a big challenge, especially where infrastructure is limited. It can even make up to 80% of total vaccination program costs. New vaccine types, like mRNA and viral vectors, have brought their own stability problems that traditional liquid formulations just can't handle. So, there's a growing focus on making solid dosage forms that don't need as much refrigeration [23, 5]. Spray drying is becoming a practical way to make these stable powder vaccines [1, 7].
2. Typical Market Trends
The global vaccine market is getting bigger, expected to grow from USD 77.6 billion to 93.8 billion by 2028 [9]. This growth comes from more demand for immunization and a focus on preparing for pandemics. A big trend is making vaccines for new and emerging infectious diseases, which needs quick, scalable production [10].
There's also a big push for new ways to deliver vaccines [10]. Instead of injections, needle-free delivery to the skin or mucous membranes (like the lungs) can make the patient experience better and create a different kind of immune response where a pathogen might enter the body. Spray drying is perfect for this because it allows for "particle engineering"—creating powder particles with specific sizes and shapes ideal for inhalation or other delivery methods [15, 3]. This is a clear advantage over lyophilization (freeze-drying), which usually makes a dried cake that needs to be reconstituted before injection [12, 13, 14].
3. Current Challenges and How They Are Solved
Moving from a liquid to a spray-dried powder brings specific technical challenges. For a CMC leader, overcoming these is key to a successful program.
Maintaining Antigen Integrity: The spray drying process involves turning a liquid into fine droplets and then quickly drying them with heated gas. Heat and shear stress can damage sensitive antigens like proteins or viral vectors, making them lose their natural structure and effectiveness [16]. The solution is smart formulation design [17]. The right mix of excipients like sugars (trehalose, sucrose), amino acids, and polymers creates a protective glassy matrix around the antigen as it dries. Careful optimization of process parameters, such as inlet temperature and feed rate, is also needed to reduce exposure to harsh conditions.
Achieving Target Particle Characteristics [15, 3]: For things like pulmonary delivery, the powder's aerodynamic properties are everything. Particles usually need to be between 1 and 5 microns to reach the deep lung. Spray drying gives you direct control over particle size, density, and morphology by adjusting process conditions and formulation composition [20]. This "bottom-up" particle engineering is a big advantage over lyophilization, which needs a separate milling step to reduce particle size; a process that can introduce its own stresses.
Ensuring Long-Term Stability: A good dried vaccine needs to stay stable for its whole shelf life and be easy to reconstitute or administer. This means creating a stable, amorphous solid with low moisture. Formulation is super important here [18, 22]. Excipients are picked not just to protect during drying, but to make sure the final powder has a high glass transition temperature (Tg). This stops molecules from moving around and breaking down over time.
4. How Leukocare Can Support These Challenges
Working through spray-dried formulation development is complex and needs specific skills and tools. This is especially true for small or virtual biotech companies without in-house solid-state formulation skills, or for bigger pharma companies trying new modalities with tricky stability issues.
At Leukocare, we don't just act as a service provider; we're a strategic partner. We focus on a data-driven formulation development platform that uses predictive modeling and AI algorithms. This lets us map out the interactions between an antigen and a wide range of excipients to find the most promising stabilizer combinations before ever entering the lab.
For a fast-moving biotech leader trying to get to a BLA quickly, this means making the development path less risky. Instead of just trying things out, we build a strong formulation designed for stability and easy manufacturing right from the start. If you're a mid-size biotech company hitting capacity limits or dealing with a tricky new modality, we offer the specialized know-how needed to solve a specific problem without messing up current partnerships. We can jump in to handle extra projects or specific challenges, giving you reliable, data-backed results. We prefer to show you rather than just tell you, often starting with a pilot project to prove our worth before doing more.
5. Value Provided to Customers
Our job is to turn formulation science into real value for our customers' development programs.
A Faster, Cleaner Path to the Clinic and Market: Our predictive approach cuts down on the number of experiments needed, saving valuable time and expensive drug substance. By designing for stability and regulatory success from the very beginning, we help you create a strong CMC package that's ready for filing. We say it directly: "We help you reach BLA faster: with a formulation designed by science, guided by data, and built for regulatory success."
Data-Informed Decision-Making: For small or early-stage biotechs, having a strong CMC story for investors is crucial. We give you the structured data and clear documentation you need to show you really understand the product. It's not about fancy words; it's about true understanding that gives investors and regulators confidence. We promise to deliver "structure, speed, and substance, driven by data, and delivered with reliability."
Solving Complex Modality Challenges: When you're dealing with a new modality like a viral vector or RNA-based product, you'll encounter internal uncertainty and generic pitches from vendors. We don't use templates [23, 5]. We team up with your group to guide your modality path with real data, custom formulation design, and deep technical know-how in areas like vectors and ADCs.
By working closely with CMC and Drug Product teams, we help make the theoretical benefits of spray drying a practical reality for your vaccine candidate.
FAQ
1. What makes a vaccine candidate good for spray drying?
Nearly any biologic can be considered for spray drying, but success depends heavily on the formulation. The antigen's natural stability is a start, but the main thing is designing a protective formulation with the right excipients. This helps it handle the process stresses and stay stable long-term in its dried form.
2. How does spray drying [18, 22] stack up against lyophilization for vaccines?
They work well together. Lyophilization is a common, gentle process perfect for molecules sensitive to heat. But it's slow, batch-based, and makes a cake that needs to be reconstituted [24]. Spray drying is a fast, continuous process that provides strong particle engineering capabilities. This makes it great for making powders for needle-free delivery methods like inhalation [15, 3]. Even though it uses higher temperatures, modern formulation strategies can effectively protect even sensitive biologics [15, 3].
3. When should we think about a spray-dried formulation [25]?
It's best to think about this early on. Bringing spray-dried formulation development in early helps make the program less risky and lets you build a full data package from the start. Thinking about the final product format and stability goals during preclinical or Phase 1 development can stop expensive reformulations later and make the path to regulatory approval smoother [26].
4. How does an AI platform help predict stability?
Our platform uses machine learning algorithms trained on lots of internal data. It models the complex interactions between the vaccine antigen and hundreds of potential excipients. By looking at these interactions, the system can predict which stabilizer combinations will best protect the antigen's structure and function during spray drying and storage. This lets us smartly design and screen formulations on the computer, focusing lab work on the best candidates and speeding up the development timeline.
